J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition could bolster the stent portfolio of Johnson & Johnson's Cordis unit, helping it retain top-tier market share as a flurry of new competitors joins the market. Conor expects to submit an application to FDA next year for its paclitaxel-eluting, cobalt-chromium coronary stent with a bioabsorbable polymer coating, which has yet to show any cases of late stent thrombosis in clincial trials.